Target Validation Information
Target ID T96788
Target Name mRNA of HER2
Target Type
Clinical Trial
Drug Potency against Target BMS-536924 Drug Info IC50 = 17100 nM [527711]
4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole Drug Info IC50 = 13500 nM [528580]
4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole Drug Info IC50 = 11000 nM [528580]
4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole Drug Info IC50 = 6600 nM [528580]
AG-213 Drug Info IC50 = 5700 nM [529134]
(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine Drug Info IC50 = 1300 nM [526072]
4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide Drug Info IC50 = 1880 nM [530574]
CL-387785 Drug Info IC50 = 17 nM [528037]
17-allylamino-17-desmethoxy-geldanamycin Drug Info IC50 = 31 nM [529815]
HKI-272 Drug Info IC50 = 59 nM [529214]
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide Drug Info IC50 = 2.2 nM [525502]
4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole Drug Info IC50 = 7900 nM [528580]
PD-168393 Drug Info IC50 = 5.7 nM [525502]
References
Ref 527711J Med Chem. 2005 Sep 8;48(18):5639-43.Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
Ref 528580Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. Epub 2006 Dec 15.Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase.
Ref 528580Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. Epub 2006 Dec 15.Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase.
Ref 528580Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. Epub 2006 Dec 15.Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase.
Ref 529134Eur J Med Chem. 2008 Jul;43(7):1478-88. Epub 2007 Sep 29.Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors.
Ref 526072Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
Ref 530574Bioorg Med Chem. 2010 Jan 15;18(2):880-6. Epub 2009 Nov 22.Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumoragents.
Ref 528037J Med Chem. 2006 Feb 23;49(4):1475-85.Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
Ref 529815Bioorg Med Chem. 2009 Mar 15;17(6):2225-35. Epub 2008 Nov 6.Discovery and development of heat shock protein 90 inhibitors.
Ref 529214Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. Epub 2007 Dec 6.Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Ref 525502J Med Chem. 1999 May 20;42(10):1803-15.Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding siteof the epidermal growth factor receptor.
Ref 528580Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. Epub 2006 Dec 15.Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase.
Ref 525502J Med Chem. 1999 May 20;42(10):1803-15.Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding siteof the epidermal growth factor receptor.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.